Clinical Trial Detail

NCT ID NCT02137837
Title S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
Recruitment Suspended
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Southwest Oncology Group
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Everolimus

Fulvestrant + Everolimus + Anastrozole

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST